925216-77-9

Upstream product

• 97-00-7 1-chloro-2,4-dinitro-benzene 
• 41838-46-4 4-Amino-1-methylpiperidine 
• 925216-76-8 N-(2,4-dinitrophenyl)-1-methylpiperidin-4-amine 

Downstream Products

• 925216-78-0 2-(4-ethoxyphenyl)-N-(2-(1-methylpiperidin-4-ylamino)-5-nitrophenyl)acetamide 

Relevant academic research and scientific papers

NOpiates: Novel dual action neuronal nitric oxide synthase inhibitors with μ-opioid agonist activity

A novel series of benzimidazole designed multiple ligands (DMLs) with activity at the neuronal nitric oxide synthase (nNOS) enzyme and the μ-opioid receptor was developed. Targeting of the structurally dissimilar heme-containing enzyme and the μ-opioid GPCR was predicated on the modulatory role of nitric oxide on μ-opioid receptor function. Structure-activity relationship studies yielded lead compound 24 with excellent nNOS inhibitory activity (IC50 = 0.44 μM), selectivity over both endothelial nitric oxide synthase (10-fold) and inducible nitric oxide synthase (125-fold), and potent μ-opioid binding affinity, Ki = 5.4 nM. The functional activity as measured in the cyclic adenosine monosphospate secondary messenger assay resulted in full agonist activity (EC50 = 0.34 μM). This work represents a novel approach in the development of new analgesics for the treatment of pain.

Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity

The present invention relates to benzimidazole compounds having dual nitric oxide synthase (NOS) inhibitory activity and agonist activity at the mu-opioid receptor, to pharmaceutical and diagnostic compositions containing them, and to their medical use, particularly as compounds for the treatment or prevention of chronic pain, acute pain, migraine, and neuropathic pain.